Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Allergan Inc. (AGN) Will Not Succeed in Delaying Stockholders’ Special Meeting: Pershing Square and Valeant Pharmaceuticals Intl Inc (VRX) Response

In a new filing with the U.S. Securities and Exchange Commission, Pershing Square, managed by Bill Ackman, has disclosed its and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) response to a recent announcement by Allergan Inc. (NYSE:AGN) regarding special meeting of stockholders and its court request to block Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Pershing Square from voting shares acquired in violation of insider trading laws.

PERSHING SQUARE

On August 26, Allergan Inc. (NYSE:AGN) announced that it asked the United States District Court for the Central District of California to set an expedited schedule for discovery and a motion for a preliminary injunction against Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Pershing Square, and William A. Ackman for violations of the federal securities laws.

Allergan Inc. (NYSE:AGN) planned to seek an order preventing Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Pershing Square, Mr. Ackman, and other entities affiliated with them from exercising any rights or benefits associated with Allergan Inc. (NYSE:AGN) shares that have been acquired unlawfully as the company claimed. Such an order would prevent Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Pershing Square, Mr. Ackman from voting their shares in any special meeting.

In addition, Allergan Inc. (NYSE:AGN) said it will hold a special meeting of stockholders on December 18, 2014. The company has established an October 27, 2014, record date for stockholders entitled to vote at the special meeting. The company’s stockholders would be asked, among other things, to remove a majority of the company’s existing directors in connection with Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) unsolicited exchange offer to acquire all outstanding common shares of Allergan Inc. (NYSE:AGN) for 0.83 shares of Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) common stock and $72.00 in cash, or subject to proration, an amount of cash or a number of Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) common shares with the implied value set forth in the exchange offer.

In response, Pershing Square and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stated that “we are confident that Allergan’s desperate attempts to delay or prevent a special meeting of stockholders will not succeed, and that the special meeting will be held not later than December 18. It is apparent that Allergan fears letting its stockholders have a voice, and we believe that its transparent efforts to prevent that will not stand.”

In its recent 13F filing, Pershing Square reported ownership of 28.88 million shares of Allergan Inc. (NYSE:AGN).

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!